ADHD(Aelis Farma)(ADHD(Aelis Farma)) - 药物靶点：CB1_在研适应症：注意缺陷障碍伴多动_专利_临床

概要

基本信息

药物类型

化学药

别名-

靶点

CB1

作用机制

CB1拮抗剂(大麻素受体CB1拮抗剂)

治疗领域

其他疾病

在研适应症

注意缺陷障碍伴多动

非在研适应症-

原研机构

Aelis Farma SA

在研机构

Aelis Farma SA

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 ADHD(Aelis Farma) 相关的临床结果

登录后查看更多信息

100 项与 ADHD(Aelis Farma) 相关的转化医学

登录后查看更多信息

100 项与 ADHD(Aelis Farma) 相关的专利（医药）

登录后查看更多信息

3

项与 ADHD(Aelis Farma) 相关的文献（医药）

2024-11-01·Asian Journal of Psychiatry

Global burden of ADHD medication-associated cardiovascular disease, 1967–2023: A comparative analysis using the WHO pharmacovigilance database

Article

作者: Acharya, Krishna Prasad ; Park, Jaeyu ; Kim, Hyeon Jin ; Cho, Hanseul ; Jeong, Yi Deun ; Lee, Hayeon ; Hwang, Jiyoung ; Kang, Jiseung ; Yon, Dong Keon ; Udeh, Raphael ; Boyer, Laurent ; Fond, Guillaume ; Lee, Kyeongmin ; Hwang, Hui-Jeong

BACKGROUND:

Despite the widespread use of attention-deficit hyperactivity disorder (ADHD) medications and their known sympathomimetic effects on the cardiovascular system, cardiovascular risk assessment of these medications using comprehensive global data is limited. This study investigated the association between individual ADHD medications and cardiovascular disease (CVD) using global pharmacovigilance data.

METHODS:

Reports from the World Health Organization international pharmacovigilance database were utilized (1967-2023; total reports, n=131,255,418). Reporting odds ratios (ROR), and information components (IC) were calculated to evaluate the association between each medication and specific CVDs.

RESULTS:

We identified 13,344 CVD cases related to ADHD medications out of 146,489 cases of all reports on ADHD medications. Cumulative reports on ADHD medications have shown a steady increase, notably in adults since 2010. ADHD medications were associated with a higher risk of CVD overall (ROR [95 % CI], 1.60 [1.58-1.63]; IC [IC_0.25], 0.63 [0.60]), with a higher association observed in females than in males. Among specific CVDs, all drugs were associated with an increased risk of torsade de pointes/QT prolongation, cardiomyopathy, and myocardial infarction. Conversely, heart failure, stroke, and cardiac death/shock were exclusively associated with amphetamines. Lisdexamfetamine showed a weaker association with all CVDs compared to amphetamines, and methylphenidate exhibited the lowest overall association with CVD. Atomoxetine had the second-highest association with torsade de pointes/QT prolongation.

CONCLUSIONS:

The associations between CVDs and ADHD medications vary, with amphetamines posing a higher risk, while lisdexamfetamine and methylphenidate exhibit better safety profiles.

2024-05-01·Bipolar disorders

Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force

Review

作者: Guglielmo, Riccardo ; Miskowiak, Kamilla W ; Lafer, Beny ; Hasler, Gregor ; Gallagher, Peter ; López-Jaramillo, Carlos ; Balanzá-Martínez, Vicent ; Vieta, Eduard ; Lewandowski, Kathryn E ; Porter, Richard J ; Martinez-Aran, Anabel ; Obel, Zacharias K ; Kessing, Lars V ; Douglas, Katie ; Bonnin, Caterina Del Mar ; Purdon, Scot E ; Bowie, Christopher R ; Dols, Annemieke ; Sumiyoshi, Tomiki ; Burdick, Katherine E ; Schaffer, Ayal ; Young, Allan H ; Van Rheenen, Tamsyn E ; Torres, Ivan J ; Stokes, Paul R A ; Carvalho, Andre F ; McIntyre, Roger S ; Yatham, Lakshmi N

Abstract:

Background:

Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention‐deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off‐label ADHD therapies in BD.

Methods:

We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials.

Results:

Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment‐related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro‐cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias.

Conclusions:

Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.

2014-08-01·JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY

Stimulant ADHD medication and risk for substance abuse.

Article

作者: Långström, Niklas ; D'Onofrio, Brian ; Chang, Zheng ; Serlachius, Eva ; Larsson, Henrik ; Lichtenstein, Paul ; Halldner, Linda ; Fazel, Seena

BACKGROUND:

There are persistent concerns of long-term effects of stimulant ADHD medication on the development of substance abuse.

METHODS:

Using Swedish national registers, we studied all individuals born between 1960 and 1998 and diagnosed with ADHD (26,249 men and 12,504 women). We investigated the association between stimulant ADHD medication in 2006 and substance abuse during 2009. Substance abuse was indexed by substance-related death, crime, or hospital visits.

RESULTS:

ADHD medication was not associated with increased rate of substance abuse. Actually, the rate during 2009 was 31% lower among those prescribed ADHD medication in 2006, even after controlling for medication in 2009 and other covariates (hazard ratio: 0.69; 95% confidence interval: 0.57-0.84). Also, the longer the duration of medication, the lower the rate of substance abuse. Similar risk reductions were suggested among children and when investigating the association between stimulant ADHD medication and concomitant short-term abuse.

CONCLUSIONS:

We found no indication of increased risks of substance abuse among individuals prescribed stimulant ADHD medication; if anything, the data suggested a long-term protective effect on substance abuse. Although stimulant ADHD medication does not seem to increase the risk for substance abuse, clinicians should remain alert to the potential problem of stimulant misuse and diversion in ADHD patients.

100 项与 ADHD(Aelis Farma) 相关的药物交易

登录后查看更多信息